Establishing a Longitudinal Cohort Study of Lung Cancer Using Tissue and Peripheral Blood Metabolomics.

Last updated: February 24, 2025
Sponsor: The First Affiliated Hospital of Guangzhou Medical University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Non-small Cell Lung Cancer

Lung Cancer

Cancer

Treatment

Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.

Clinical Study ID

NCT06843707
LungMet
2025-01-12
  • Ages 18-75
  • All Genders

Study Summary

This study will utilize tissue and peripheral blood samples for metabolomics analysis and establish a longitudinal metabolomics cohort at multiple critical treatment time points to comprehensively investigate the role of metabolomics in the diagnosis, prognosis, and therapeutic monitoring of lung cancer. By profiling metabolic alterations, this study aims to identify potential biomarkers for distinguishing benign and malignant lung nodules, predicting therapeutic efficacy, and assessing long-term prognosis. Key time points include initial screening for lung nodules, postoperative evaluation to predict treatment outcomes, and therapeutic monitoring to assess efficacy after medication or other interventions. Through these analyses, the study seeks to uncover underlying metabolic mechanisms and provide valuable insights into personalized lung cancer management.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Signing of the informed consent form;

  2. Male or female, aged 18-75 years;

  3. Patients with lung nodules confirmed by CT examination;

  4. Good preoperative pulmonary function cooperation and complete reporting;

  5. Preoperative chest single/dual phase CT scans without significant artefacts and withcomplete imaging;

  6. The interval between preoperative pulmonary function and single/dual phase CT scansdoes not exceed one month.

Exclusion

Exclusion Criteria:

  1. Poor preoperative pulmonary function cooperation or missing reports;

  2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or imageomission;

  3. The interval between preoperative pulmonary function and single/dual phase CT scansexceeds one month;

  4. Complication with severe respiratory disorders (such as lung transplantation,pneumothorax, giant bullae, etc.);

  5. Coexisting with other severe functional impairments;

  6. Patients with obstructive lesions such as airway or esophageal stenosis;

(8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.

Study Design

Total Participants: 2500
Treatment Group(s): 1
Primary Treatment: Monitoring serum metabolites in lung cancer patients using tissue and peripheral blood samples.
Phase:
Study Start date:
January 01, 2024
Estimated Completion Date:
December 31, 2027

Connect with a study center

  • the First Affiliated of Guangzhou Medical University

    Guangzhou, Guangdong 510120
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.